Cannabinoide reduzieren den Opioidverbrauch bei älteren Schmerzpatienten

Gastmeier et al. ·Der Schmerz Impact 0.6

Clear benefit GRADE Low 10 citations

Samplen = 178 Pat.

Duration366 days

EndpointOpioid consumption

Blindingn.a.

DesignRetrospektive Kohortenstudie

Cannabinoidvollspektrum

Max. dose13.6 mg

Key finding

Cannabinoids significantly reduced opioid consumption by 50 % (24 mg morphine equivalents/day) in comedicated patients.

Summary

Retrospective analysis of n=178 pain patients (median 72 years, range 26-96) over a median of 366 days of cannabinoid therapy (dronabinol, nabiximols, extracts); 115 patients (65%) received opioids in parallel (median 65 mg/day morphine equivalent). Significant opioid reduction by 24 mg/day or 50% (p<0.05), independent of cannabinoid dose, age and sex. Discontinuation rate due to adverse effects only 2.8% (n=5).

PopulationOlder pain patients from a pain therapy practice with chronic pain, n=178, median age 72 years (26–96 years), 64,8 % women

InterventionMedical cannabinoids (dronabinol, nabiximols, cannabis extracts), median 9,6 mg THC/day (oil/extract), 13,6 mg THC/day (spray), long-term therapy

OutcomeSignificant reduction of opioid consumption by 24 mg morphine equivalents/day (median) or 50 %, independent of CAM dose, sex and age

Confidence in the evidence

Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile

Sample size ★★★★★

Blinding —

Effect size Clear benefit

Citations / year ★★★★★

Authors

Gastmeier K, Gastmeier A, Rottmann F et al

DOI 10.1007/s00482-022-00642-0↗

Design: Retrospektive Kohortenstudie

The impediment to action advances action. — Marcus Aurelius